CLAIMS

1. A crystalline form of a compound of Formula (I):



;

wherein the crystalline form is of Form A, having an X-ray powder diffraction pattern comprising characteristic peaks at 4.0° ± 0.2° 2θ, 10.5° ± 0.2° 2θ, and 12.0° ± 0.2° 2θ.

2. The crystalline form according to claim 1, wherein the X-ray powder diffraction pattern further comprises a peak at 12.6° ± 0.2° 2θ.

3. The crystalline form according to claim 1 or claim 2, wherein the X-ray powder diffraction pattern further comprises a peak at 16.1° ± 0.2° 2θ.

4. The crystalline form according to any one of claims 1 to 3, wherein the X-ray powder diffraction pattern further comprises a peak at 18.0° ± 0.2° 2θ.

5. The crystalline form according to any one of claims 1 to 4, wherein the X-ray powder diffraction pattern comprises peaks at 4.0, 10.5, 12.0, 12.6, 15.5, 16.1, and 18.0°, with each peak measured to ± 0.2° 2θ.

6. The crystalline form according to any one of claims 1 to 5, wherein the X-ray powder diffraction pattern is substantially as illustrated in Fig. 2.

7. The crystalline form according to any one of claims 1 to 6, wherein the DSC thermogram of crystalline Form A has a single endothermic peak at about 222 °C ± 2 °C.

8. The crystalline form according to any one of claims 1 to 7, wherein the crystalline form is an anhydrate.

9. A pharmaceutical composition comprising: a) crystalline Form A as defined in any one of claims 1 to 8; and b) one or more pharmaceutically acceptable excipients, carriers, or diluents.

10. The pharmaceutical composition according to claim 9, wherein the pharmaceutical composition comprises at least about 50 wt% of crystalline Form A as defined in any one of claims 1 to 8.

11. The pharmaceutical composition according to claim 9 or claim 10, wherein at least about 80 mol% of the compound of Formula (I) in the composition is crystalline Form A as defined in any one of claims 1 to 8.

12. A crystalline form as defined in any one of claims 1 to 8, or a pharmaceutical composition as defined in any one of claims 9 to 11, for use in therapy.

13. A crystalline form as defined in any one of claims 1 to 8, or a pharmaceutical composition as defined in any one of claims 9 to 11, for use in the treatment and/or prevention of an inflammatory or autoimmune disorder, a neurological or neurodegenerative disorder, pain or a nociceptive disorder, a cardiovascular disorder, a metabolic disorder, an ocular disorder, or an oncological disorder.

14. A process of manufacturing a crystalline form as defined in any one of claims 1 to 8, wherein the process comprises:

a) combining compound of Formula (I):



with a solvent to form a mixture;

b) heating the mixture to a temperature of about 50 °C or greater;

c) cooling the mixture to ambient temperature or lower.

15. The process of claim 14, wherein the solvent is selected from acetonitrile, ethyl acetate and propyl acetate, and is optionally acetonitrile.

16. The process according to either claim 14 or claim 15, wherein the process further comprises adding a seed crystal to the mixture, wherein the seed crystal is a crystal of Form A as defined in any one of claims 1 to 8.